Dr. Mark Lim


Dr. Lim received his Ph.D. at Boston University in vascular cell biology and proteomics where he gained extensive training in protein isolation, separation and detection as well as mass spectrometry based protein analysis. During this period he developed and characterized novel reversible colorimetric and luminescent metal chelate-based protein dyes for proteomics which are widely used in the Life Sciences. His early work at AmberGen was instrumental in the successful development of its photocleavable linker (PC-Linkers™) and protein engineering  product lines including PC-Biotin-NHS, PC-Phosphoramidites and fluorescent tRNAs which have been commercialized in partnership with several major vendors of biomolecular reagents. His more recent R&D efforts at AmberGen led to the discovery, validation and patenting of two new autoantigen biomarkers for the autoimmune liver disease PBC, which are currently undergoing FDA-clearance. Dr. Lim is co-inventor on 11 issued U.S. patents in the biotechnology space and the author of 15 peer-reviewed scientific journal articles. As CSO, Dr. Lim is leading AmberGen’s development of blood-based multiplex immunoassays for allergy, cancer and autoimmune disease as well as the development of Bead-AMS™, a proteome-wide method of drug and drug-target discovery.